SACUBITRIL/VALSARTAN IN THE TREATMENT OF RESISTANT HYPERTENSION: RAISING STAR OR ILLUSION?

Klinik für Innere Medizin II, Cardiology Department, Universitätsklinikum Ulm; Department of Medicine and Surgery, University of Milano-Bicocca

Sacubitril/valsartan has been recognized for its role in treating heart failure with reduced ejection fraction, and recent studies suggest it may also benefit patients with resistant hypertension. The editorial reviews the mechanisms by which this combination therapy may improve blood pressure control and discusses the challenges faced in treating resistant hypertension, particularly in hemodialysis patients. It emphasizes the need for further research to establish the efficacy of sacubitril/valsartan in this specific patient population.